$2.800
-0.124 (-4.44%)收盘时
QTI 资讯
QTI 事件
QT Imaging Reports Q2 Revenue of $7.4M, Below Estimates
Reports Q2 revenue $7.4M, two estimates $7.6M, "Our second quarter results demonstrate continued execution and the growing commercial momentum of QT Imaging. Revenue more than doubled year-over-year to $7.4 million, and we shipped fifteen Breast Acoustic CT scanners during the quarter, compared with eight in the prior-year period," said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. "We also took important steps to support continued growth, completing a $10 million public offering, expanding our direct U.S. sales organization, and securing regulatory authorization in Israel and Saudi Arabia. At the same time, we generated new evidence demonstrating less than 1% variability in Speed of Sound measurements across our scanners, successfully completed our first routine FDA inspection with zero Form 483 observations, and expanded manufacturing capacity through our new 22,000-square-foot facility. These are tangible steps toward scaling Breast Acoustic CT commercially while building the clinical, regulatory and operational foundation for broader adoption."
QT Imaging Appoints New VPs to Advance U.S. Sales Strategy
QT Imaging advanced the direct U.S. commercial strategy for its Breast Acoustic CT Scanner with the appointment of Jason Dyer as Vice President, VP, Regional Sales East and Dave Reinhart as Vice President, VP, Regional Sales West. Both executives joined QT Imaging in July 2026 and report to Satrajit Misra, the Company's Chief Commercial Officer.
QT Imaging Appoints Julia Albright as Chief Science Officer
QT Imaging announced the appointment of Julia Albright, Ph.D., as Chief Science Officer, CSO, effective July 27, 2026. Dr. Albright most recently served as Managing Director of the HIT and Enterprise Solutions Business Unit at Canon Medical Systems, USA.
QT Imaging Secures Israeli Health Ministry Registration Until 2028
QT Imaging Holdings announced that the Israeli Ministry of Health has granted registration for the Company's scanner, authorizing commercialization of the system in Israel through February 2, 2028. The approval is based on the Company's existing U.S. FDA clearance and applicable Israeli regulatory requirements.
QT Imaging Successfully Completes FDA Routine Inspection with Zero Observations
QT Imaging announced the successful completion of its first routine inspection by the FDA, with zero Form 483 observations. The FDA inspection reviewed QT Imaging's Quality Management System and related processes that support the company's operations, with no Form 483 observations issued. The inspector also provided positive feedback regarding the organization of QT Imaging's QMS and the company's responsiveness throughout the inspection process. An FDA Form 483 is issued at the conclusion of an inspection when an FDA investigator has observed conditions that may constitute violations of the Food, Drug and Cosmetic Act and related regulations.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。